On Monday, Akero Therapeutics Inc (NASDAQ: AKRO) was 4.22% up from the session before settling in for the closing price of $39.85. A 52-week range for AKRO has been $17.86 – $58.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at -12.23%. With a float of $70.76 million, this company’s outstanding shares have now reached $79.68 million.
Let’s look at the performance matrix of the company that is accounted for 63 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Akero Therapeutics Inc (AKRO) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Akero Therapeutics Inc stocks. The insider ownership of Akero Therapeutics Inc is 11.19%, while institutional ownership is 88.99%. The most recent insider transaction that took place on May 12 ’25, was worth 4,782,000. Before that another transaction happened on May 07 ’25, when Company’s Senior VP, Commercial Strategy sold 8,000 for $42.49, making the entire transaction worth $339,950. This insider now owns 33,492 shares in total.
Akero Therapeutics Inc (AKRO) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.18% during the next five years compared to -5.28% drop over the previous five years of trading.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
You can see what Akero Therapeutics Inc (AKRO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 19.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.75, a number that is poised to hit -0.99 in the next quarter and is forecasted to reach -4.64 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Akero Therapeutics Inc (NASDAQ: AKRO) saw its 5-day average volume 1.43 million, a positive change from its year-to-date volume of 1.35 million. As of the previous 9 days, the stock’s Stochastic %D was 18.00%. Additionally, its Average True Range was 2.57.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 54.48%, which indicates a significant increase from 35.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.68% in the past 14 days, which was lower than the 122.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $41.66, while its 200-day Moving Average is $34.41. Nevertheless, the first resistance level for the watch stands at $42.45 in the near term. At $43.38, the stock is likely to face the second major resistance level. The third major resistance level sits at $44.58. If the price goes on to break the first support level at $40.33, it is likely to go to the next support level at $39.13. Assuming the price breaks the second support level, the third support level stands at $38.20.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
There are 79,679K outstanding shares of the company, which has a market capitalization of 3.31 billion. As of now, sales total 0 K while income totals -252,060 K. Its latest quarter income was 0 K while its last quarter net income were -70,020 K.
